Vyvgart shines in CIDP study, teeing up another potential nod for Argenx's pipeline in a product

From its initial nod in generalized myasthenia gravis (gMG) in 2021 to a subcutaneous approval this summer—and now, a stellar showing in a second neuromuscular disease—Argenx’s flagship drug Vyvgart is proving its merit as a potential franchise.